Complex issues: use of oppositions, protests, inter partes reviews, post-grant reviews and litigation.
Interface with regulatory exclusivity and FDA regulations. Orange Book patent listings. Patent term extension applications.
IP aspects of licenses and collaborations from term sheets to agreements, sponsored research, technology and material transfer agreements.
Antisense, RNAi, miRNA, ncRNA
Peptides and chemically modified derivatives
Vaccines and immune therapies
Chemical pharmaceutical products
Therapeutic methods using traditional pharmaceuticals or biologics
Recombinant manufacturing processes and vectors
Example Client Experiences
Acquisition of Public Company
Led team that built an extensive patent portfolio for InterMune, Inc. relating to ESBRIET, a drug that treats idiopathic pulmonary fibrosis (IPF).
Accelerated examination to obtain patent grants in time for the drug’s approval.
Handled the IP due diligence relating to InterMune’s acquisition by a global pharma company for US$8.3 billion.
Acquisition of Startup
Built patent portfolio for Marcadia Biotech, Inc., a startup based on university technology.
Handled IP aspects of collaborations with two of the ten largest pharmaceutical companies in the world.
Helped negotiate licenses and other agreements.
Handled the IP due diligence surrounding their acquisition in 2010 by a global biopharma company for up to $537 million.
Startup to IPO
Advised CRISPR Therapeutics on its intellectual property strategy since its formation.
CRISPR Therapeutics is a biopharmaceutical company focused on the breakthrough gene-editing technology CRISPR-Cas9.
Patenting Systems of the Future
Co-represented a university and its licensee Electrochaea in obtaining patents that cover their innovative microorganism-based technology that converts electricity to methane gas. Electrochaea launched the first commercial scale power-to-gas project.